ClinVar Miner

Submissions for variant NM_000102.4(CYP17A1):c.62G>A (p.Arg21Lys) (rs61754263)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Illumina Clinical Services Laboratory,Illumina RCV000303229 SCV000360146 uncertain significance Congenital adrenal hyperplasia 2016-06-14 criteria provided, single submitter clinical testing The c.62G>A (p.Arg21Lys) variant was reported in a homozygous state in a patient with congenital adrenal hyperplasia due to 17alpha-hydroxylase/17,20-lyase deficiency (Nuzzo et al. 2009). Studies of available family members showed that the patient's unaffected mother and sister were both heterozygous for this variant. Control data are unavailable for this variant, which is reported at a frequency of 0.00298 in the European population of the 1000 Genomes Project. The evidence for this variant is limited. The p.Arg21Lys variant is therefore classified as a variant of unknown significance but suspicious for pathogenicity for congenital adrenal hyperplasia.
GeneDx RCV000488920 SCV000576975 uncertain significance not provided 2017-04-13 criteria provided, single submitter clinical testing The R21K variant in the CYP17A1 gene has been reported previously, using alternate nomenclature R21L, in the homozygous state in an adult with congenital adrenal hyperplasia who initially presented with primary amenorrhea, hypokalemic myopathy and hypertension (Nuzzo et al., 2009). The R21K variant is observed in 95/66698 (0.14%) alleles from individuals of non-Finnish European background, in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The R21K variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution occurs at a position that is not conserved. In silico analysis predicts this variant likely does not alter the protein structure/function. We interpret R21K as a variant of uncertain significance.
GenomeConnect, ClinGen RCV001249435 SCV001423439 not provided Deficiency of steroid 17-alpha-monooxygenase no assertion provided phenotyping only Variant interpretted as Uncertain significance and reported on 04-29-2017 by Lab or GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.